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Background-—Epidemiological evidence suggests a cardioprotective role of a-linolenic acid (ALA), a plant-derived x-3 fatty acid. It
is unclear whether ALA is beneﬁcial in a background of high marine x-3 fatty acids (long-chain n-3 polyunsaturated fatty acids)
intake. In persons at high cardiovascular risk from Spain, a country in which ﬁsh consumption is customarily high, we investigated
whether meeting the International Society for the Study of Fatty Acids and Lipids recommendation for dietary ALA (0.7% of total
energy) at baseline was related to all-cause and cardiovascular disease mortality. We also examined the effect of meeting the
society’s recommendation for long-chain n-3 polyunsaturated fatty acids (≥500 mg/day).
Methods and Results-—We longitudinally evaluated 7202 participants in the PREvencion con DIeta MEDiterranea (PREDIMED) trial.
Multivariable-adjustedCox regressionmodelswereﬁtted to estimate hazard ratios. ALA intake correlated towalnut consumption (r=0.94).
During a 5.9-y follow-up, 431 deaths occurred (104 cardiovascular disease, 55 coronary heart disease, 32 sudden cardiac death, 25
stroke). Thehazard ratios formeetingALA recommendation (n=1615, 22.4%)were0.72 (95%CI 0.56–0.92) for all-causemortality and0.95
(95%CI 0.58–1.57) for fatal cardiovascular disease. The hazard ratios formeeting the recommendation for long-chain n-3 polyunsaturated
fatty acids (n=5452, 75.7%) were 0.84 (95%CI 0.67–1.05) for all-causemortality, 0.61 (95%CI 0.39–0.96) for fatal cardiovascular disease,
0.54 (95% CI 0.29–0.99) for fatal coronary heart disease, and 0.49 (95% CI 0.22–1.01) for sudden cardiac death. The highest reduction in
all-cause mortality occurred in participants meeting both recommendations (hazard ratio 0.63 [95% CI 0.45–0.87]).
Conclusions-—In participants without prior cardiovascular disease and high ﬁsh consumption, dietary ALA, supplied mainly by
walnuts and olive oil, relates inversely to all-cause mortality, whereas protection from cardiac mortality is limited to ﬁsh-derived
long-chain n-3 polyunsaturated fatty acids.
Clinical Trial Registration-—URL: http://www.Controlled-trials.com/. Unique identiﬁer: ISRCTN35739639. ( J Am Heart Assoc.
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ORIGINAL RESEARCH
C onsistent evidence suggests that fatal coronary heartdisease (CHD), the leading cause of death worldwide,
can be prevented by various dietary components.1 Consump-
tion of ﬁsh and long-chain n-3 (x-3) polyunsaturated fatty
acids (LCn-3PUFA), mainly eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), has been associated with a
lower risk of CHD, particularly sudden cardiac death (SCD) in
persons without prior cardiovascular disease (CVD).2,3
a-Linolenic acid (ALA) is a shorter chain n-3 fatty acid readily
available from plant sources. Although the conversion of ALA
into longer chain derivatives is limited (<5%), increased
consumption of ALA translates into modest increases in the
concentrations of EPA, but not DHA, in plasma and cell pools
in a process controlled by both endocrine and dietary
factors.4 By enhancing EPA synthesis, ALA might be cardio-
protective in persons who do not eat ﬁsh; however, the issue
of whether ALA is protective on its own, particularly if the diet
provides sufﬁcient amounts of EPA and DHA, remains
unsettled.5 As reported in a recent meta-analysis of obser-
vational studies, higher ALA intake is associated with a
moderately lower risk of CVD, particularly fatal CHD.6 The
unexplained high heterogeneity in this meta-analysis high-
lights the need for additional well-designed observational
studies and large randomized clinical trials to evaluate the
effects of ALA intake on the primary prevention of CVD.
We hypothesized that ALA intake contributes to the
primary prevention of fatal CVD and all-cause mortality, even
in a background of high intake of ﬁsh-derived LCn-3PUFA,
such as that reported in the Spanish population.7–9 To test
this hypothesis, we longitudinally investigated the association
of baseline dietary ALA intake with all-cause and cardiovas-
cular mortality in a cohort of older persons at high cardio-
vascular risk enrolled into the PREvencion con DIeta
MEDiterranea (PREDIMED) study, a randomized nutrition
intervention trial for the primary prevention of CVD conducted
in Spain.10 In addition, we examined the effects on mortality
of exposure to LCn-3PUFA.
Methods
Setting
This study was conducted within the frame of the PREDIMED
trial, the design of which has been described in detail.11
Brieﬂy, the PREDIMED study is a multicenter, parallel-group,
randomized clinical trial to assess the effects of the Mediter-
ranean diet (MedDiet) on the primary prevention of CVD in a
high-risk cohort (PREDIMED website, http://www.pred-
imed.es; ISRCTN registration, http://www.Controlled-trials.-
com/ISRCTN35739639). From October 2003 to June 2009, a
total of 8713 candidates were screened for eligibility, and
7447 were randomly assigned to 1 of the 3 interventions.
Participants were men aged 55 to 80 years and women aged
60 to 80 years at high cardiovascular risk but with no CVD at
enrollment. Criteria for eligibility were the presence of either
type 2 diabetes or at least 3 cardiovascular risk factors:
current smoking, hypertension, dyslipidemia, overweight or
obesity, and family history of early onset CHD. Main exclusion
criteria were a prior history of CVD, any severe chronic illness,
substance abuse, and history of allergy or intolerance to olive
oil or nuts (supplemental foods given in 2 arms of the study).
The study protocol was conducted according to the guidelines
laid down in the Declaration of Helsinki, and all procedures
were approved by the institutional review boards of all the
recruiting centers. Written informed consent was obtained
from all study participants.
Assessment of Risk Factors
Participants were considered to have diabetes, hyperlipi-
demia, or hypertension if they had a previous diagnosis of
these conditions and/or they were treated with antidiabetic,
cholesterol-lowering, or antihypertensive agents, respectively.
Smoking status was categorized into never, current, or past
smoking, according to self-reports. Physical activity was
determined with the Minnesota Leisure-Time Physical Activity
questionnaire and expressed in minutes at a given metabolic
equivalent per day.12 Height, weight, and waist circumference
were measured with standard methods.
Dietary Intake
Dietary intake was assessed with a validated 137-item
semiquantitative food-frequency questionnaire13 administered
at baseline and yearly during follow-up. In face-to-face
interviews, participants were asked about the frequency of
consumption of each food item during the past year,
specifying usual portion sizes. Nine possibilities of frequency
were offered, ranging from never to >6 times/day. Informa-
tion on seafood products was collected in 8 items of the food-
frequency questionnaire (uncanned fatty ﬁsh; lean ﬁsh;
smoked/salted ﬁsh; mollusks; shrimp, prawn, and crayﬁsh;
octopus, baby squid, and squid; fatty ﬁsh canned in oil; fatty
ﬁsh canned in salted water) and 6 items regarding major
sources of ALA (soybean oil, walnuts, margarine, corn oil,
sunﬂower oil, olive oil). Consumption of ﬂaxseed and canola
oils was not considered because these oils are not consumed
in Spain. Nutrient intakes were computed using Spanish food
composition tables. The validation of the food-frequency
questionnaire against four 3-day food records showed energy-
adjusted intraclass correlation coefﬁcients of 0.506 and
0.728 for LCn-3PUFA and ALA, respectively (P<0.001, both).
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After the screening visit, suitable candidates were ran-
domly assigned to 1 of 3 interventions: MedDiet with extra
virgin olive oil, MedDiet with nuts, or control diet. Quarterly
individual and group sessions were scheduled for the 2
MedDiet groups; in them, participants were educated on how
to follow the MedDiet and received supplemental foods at no
cost. Extra virgin olive oil (1 L/week) was provided to 1 group,
and 30 g/day of mixed nuts (15 g walnuts, 7.5 g hazelnuts,
and 7.5 g almonds) were provided to the other group. During
the ﬁrst 3 years of the trial, participants in the control group
were scheduled for yearly visits in which they received a
leaﬂet explaining the low-fat diet. The realization that the
more infrequent visits in this group might be a limitation of
the trial prompted a protocol amendment in October 2006;
thereafter, participants in the control group received person-
alized advice and group sessions with the same intensity and
frequency as those in the MedDiet groups. In the quarterly
sessions, participants were educated on how to follow a low-
fat diet and received small nonfood gifts, such as kitchenware,
tableware, aprons, or shopping bags. In each session, a
dietary screener of adherence to the MedDiet was used to
track diet changes. The score was determined by 12
questions on food consumption frequency and 2 questions
on food consumption habits considered characteristic of the
MedDiet (each question scored 0 or 1).14
End Point Ascertainment
The end points of interest in the present analysis were all-
cause and total CVD mortality; fatal CHD (acute myocardial
infarction, unstable angina pectoris, and other forms of
chronic ischemic heart disease); SCD, as ascertained by the
criteria deﬁned by Buxton and collaborators15; and fatal
stroke. Information on mortality was updated yearly until
completion of the trial and every 2 years thereafter by the end
point adjudication committee, the members of which were
blinded to treatment allocation and to the dietary habits of
participants. Different sources of information were used:
yearly questionnaires and examinations for all participants,
contact with primary care physicians, yearly review of medical
records, and linkage to the National Death Index. Medical
records of deceased participants were requested. Only end
points that were conﬁrmed by the adjudication committee and
that occurred between October 1, 2003, and June 30, 2012
(date of the last update in the extended follow-up of the
PREDIMED cohort, 2 years after the end of the trial), were
included in the analyses.
Statistical Analyses
Follow-up time was calculated as the interval between the
date of randomization and the date of death, the date of the
last visit, or the last recorded clinical event of participants
still alive, whichever came ﬁrst. After excluding participants
with reported total energy intake outside predeﬁned limits
(>4000 or <800 kcal/day in men and >3500 or <500 kcal/
day in women, n=153), those with incomplete baseline
dietary data (n=78), and those with implausible intakes of
either ALA (>10 g/day) or LCn-3PUFA (>4 g/day) (n=14),
7202 study participants (n=2376 control diet, n=2469
MedDiet plus extra virgin olive oil, and n=2357 MedDiet
plus nuts) remained for inclusion in the analyses. The 2
exposures of interest were (1) meeting the International
Society for the Study of Fatty Acids and Lipids (ISSFAL)
recommendation to consume at least 500 mg/day of EPA
plus DHA for primary prevention (yes or no) and (2) meeting
the ISSFAL recommendation to have an intake of ALA of
0.7% of total energy (yes or no). Both recommendations
were released in June 2004.16
Multivariate Cox proportional hazards models were used
to assess the associations between both exposures (all
models included reciprocal adjustment for the 2 types of n-
3 examined) and the risk of the 5 prespeciﬁed end points.
We initially performed sex-speciﬁc analyses, but results by
sex were similar, and no interactions existed between sex
and any of the exposures for any of the dependent
variables (data not shown); therefore, we report pooled data
for men and women. No signiﬁcant interactions were found
between the 2 exposures of interest and the intervention
group. In all cases, analyses were stratiﬁed by recruitment
center and were adjusted for age, sex, intervention group,
body mass index, smoking status (never, former, or current
smoker), physical activity (minutes at a given metabolic
equivalent per day), total energy intake (kcal/day), history
of diabetes (yes or no), history of hyperlipidemia (yes or
no), history of hypertension (yes or no), alcohol intake (g/
day), and dietary factors (ﬁber, vegetables, fruits, and red
meat in g/day). In addition, we used Cox regression models
to assess the risk of the prespeciﬁed end points according
to the joint categories of meeting target intake recommen-
dations for ALA and LCn-3PUFA intake (yes or no) and the
intervention group (3 groups, 2 dummy variables). To verify
the proportional hazards assumption in Cox regression
models, we created time-by-covariate interactions for each
variable included into the model. When introducing products
between the variables and a linear function of time in each
model, no signiﬁcance was found for any interaction of
interest.
Baseline differences in demographic, clinical, and selected
dietary variables were assessed by ANOVA or chi-square
tests, as appropriate. The level of signiﬁcance for all
statistical tests was P<0.05 for bilateral contrasts. Analyses
were done using SPSS statistical software, version 19 (IBM
Corp).
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Results
The mean age of participants at inclusion was 67 years, and
57.5% of them were women. Of the whole cohort (n=7202),
5452 participants (75.7%) met the ISSFAL target recommen-
dation for LCn-3PUFA intake of at least 500 mg/day, whereas
1615 (22.4%) met the recommendation of ALA intake of at
least 0.7% of daily energy. Table 1 summarizes the baseline
clinical characteristics and treatment regimens of the whole
cohort and by sex. Clinical information by meeting the
recommendations can be found in Table 2. Participants
meeting the ALA recommendations were slightly older, leaner,
more physically active, and smoked less than participants
meeting the LCn-3PUFA recommendation.
Intake of energy, nutrients, and key foods are shown in
Table 3 (whole cohort and by sex) and Table 4 (by meeting
the ISSFAL recommendations). A total of 4292 participants
(60%) reported consumption of walnuts at least once per
week, whereas only 119 (<2%) reported similar consumption
of soybean oil. The main sources of ALA were walnuts (mean,
27% of total ALA), olive oil (23%), eggs and meat (20%), and
dairy products (12%). Vegetable fats other than olive oil
supplied <3% of total ALA. The Pearson correlation coefﬁ-
cients between the baseline estimated dietary ALA intake and
consumption of walnuts, soybean oil, margarine, olive oil, and
corn oil were 0.941 (P<0.001), 0.084 (P<0.001), 0.069
(P<0.001), 0.099 (P<0.001), and 0.024 (P=0.044), respec-
tively. Consumption of sunﬂower oil was unrelated to dietary
ALA. By deﬁnition of the study groups, intake of ALA and LCn-
3PUFA and their main parent foods (walnuts and seafood,
respectively) differed between groups. Compared with the
participants meeting the LCn3-PUFA recommendation, those
meeting the ALA recommendation adhered more to the
MedDiet and consumed more total fat and x-6 polyunsatu-
rated fatty acids, fruit, and ﬁber and less carbohydrate,
cereals, cholesterol, and alcoholic beverages.
During a mean follow-up of 5.9 years, we documented 431
all-cause deaths, including 104 cases of fatal CVD (55 cases
of fatal CHD, 32 cases of SCD, 25 cases of fatal stroke).
Table 5 shows mortality risks (hazard ratios [HRs]) associated
with the 2 exposures of interest. After adjusting for age, sex,
intervention group, and lifestyle variables, including intake of
relevant foods and nutrients, participants consuming at least
500 mg/day of EPA plus DHA had borderline signiﬁcant
reduction of SCD risk by 52% and signiﬁcant reductions of
fatal CVD and CHD by 39% and 46%, respectively. If the
exposure of interest was meeting the ISSFAL recommenda-
tion for dietary ALA intake of 0.7% of daily energy, multivari-
Table 1. Participant Clinical Characteristics and Treatment Regimes at Baseline by Sex
All Participants (n=7202) Men (n=3063) Women (n=4139)
Age, y 67.0 (66.9–67.2) 66.0 (65.8–66.3) 67.8 (67.6–67.9)
Weight, kg 76.7 (76.5–77.0) 82.2 (81.8–82.6) 72.7 (72.4–73.0)
Body mass index, kg/m2 30.0 (29.9–30.1) 29.3 (29.2–29.4) 30.5 (30.3–30.6)
Waist circumference, cm* 100 (100–101) 103 (103–104) 98 (98–99)
Family history of early onset CHD, n (%)† 1607 (23.0) 523 (17.6) 1084 (27.0)
Energy expenditure in physical activity, MET-min/day 231 (226–237) 310 (300–321) 173 (168–178)
Smoking status, n (%)
Current 1003 (13.9) 776 (25.3) 227 (5.5)
Former 1170 (24.6) 1477 (48.2) 293 (7.1)
Never 4429 (61.5) 810 (26.4) 3619 (87.4)
Hypertension, n (%) 5959 (82.7) 2386 (77.9) 3573 (86.3)
Use of antihypertensive drugs, n (%) 5006 (69.5) 2019 (65.9) 2987 (72.2)
Dyslipidemia, n (%) 5202 (72.2) 2031 (66.3) 3171 (76.6)
Use of statins, n (%) 2897 (40.2) 1103 (36.0) 1794 (43.3)
Type 2 diabetes, n (%) 3516 (48.8) 1674 (54.6) 1845 (44.6)
Use of oral hypoglycemic agents, n (%) 2146 (29.8) 1022 (33.4) 1124 (27.2)
Use of insulin, n (%) 374 (5.2) 153 (5.0) 221 (5.3)
Values are n (%), except for age, weight, body mass index, and physical activity, expressed as means (95% CI). CHD indicates coronary heart disease; MET-min, minutes at a given metabolic
equivalent level (units of energy expenditure in physical activity, 1 MET-min is roughly equivalent to 1 kcal).
*Data from n=6997 participants (2979 men and 4018 women).
†Data from n=6983 participants (2968 men and 4015 women).
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able-adjusted risk of all-cause mortality was signiﬁcantly
reduced by 28%. No signiﬁcant associations were found for
other outcomes. Table 6 presents the risk of all-cause
mortality for meeting none, one, or both ISSFAL recommen-
dations of n-3 fatty acid intake. Compared with participants
meeting neither recommended ALA nor LCn-3PUFA intake,
the highest reduction was observed in those meeting both
recommendations (HR 0.626 [95% CI 0.450–0.871],
P=0.005).
Figure shows the multivariate adjusted HRs for total
mortality by meeting the ISSFAL recommendation for ALA
intake at baseline according to intervention group. Compared
with the reference category (participants not meeting target
intake who were allocated to the control diet group, n=448),
participants meeting target intake who were allocated to the
MedDiet with nuts intervention group (n=648) had a border-
line decreased risk of 30% (95% CI 6 to 53) for all-cause
mortality, whereas participants meeting target intake who
were allocated to the MedDiet supplemented with extra virgin
olive oil (n=519) had a signiﬁcant 42% (95% CI 4–64)
reduction in total mortality. No signiﬁcant associations were
found for meeting the ISSFAL recommendation of LCn-3PUFA
by intervention group (data not shown).
Discussion
Our ﬁndings suggest that in an older population at high
cardiovascular risk, consuming at least 500 mg/day of LCn-
3PUFA (mainly from seafood) is associated with a borderline
signiﬁcant reduction in SCD by 52% and signiﬁcant reductions
in fatal CVD and CHD by 39% and 46%, respectively. In
addition, dietary ALA (derived mainly from walnuts followed by
olive oil) accounting for at least 0.7% of daily energy intake
was associated with a 28% reduced risk of all-cause mortality.
Importantly, the beneﬁcial effect of ALA on mortality is
observed in the context of a high intake of LCn-3PUFA.
Table 2. Baseline Demographic and Medical History by Meeting the ISSFAL Recommendations
Meeting the ISSFAL Recommendation for ALA*
Meeting the ISSFAL Recommendation for LCn-
3PUFA†
Yes (n=1615) No (n=5587) Yes (n=5452) No (n=1750)
Age, y 67.3 (67.0–67.6) 67.0 (66.8–67.1)‡ 66.7 (66.6–66.9)§ 68.0 (67.7–68.3)‡
Sex, men n (%) 682 (42.2) 2381 (42.6) 24.1 (44.6) 632 (36.1)‡
Weight, kg 74.9 (74.4–75.5) 77.3 (77.0–77.6)‡ 76.9 (76.6–77.3)§ 76.1 (75.6–76.7)‡
Body mass index, kg/m2 29.3 (29.1–29.4) 30.2 (30.1–30.3)‡ 29.9 (29.8–30.0)§ 30.1 (30.0–30.3)‡
Waist circumference, cm|| 99 (98–99) 101 (101–101)‡ 101 (100–101)§ 100 (100–101)
Family history of early-onset CHD, n (%)¶ 375 (23.2) 1232 (22.1) 1227 (22.5) 380 (21.7)
Energy expenditure in physical activity, MET-min/day 263 (251–276) 222 (216–228)‡ 236 (229–242)§ 217 (206–227)‡
Smoking status, n (%) ‡ § ‡
Current 178 (11.0) 825 (14.8) 789 (14.5) 214 (12.2)
Former 407 (25.2) 1363 (24.4) 1410 (25.9) 360 (20.6)
Never 1030 (63.8) 3399 (60.8) 3253 (59.7) 1176 (67.2)
Hypertension, n (%) 1237 (82.2) 4632 (82.9) 4484 (82.2) 1475 (84.3)‡
Use of antihypertensive drugs, n (%) 1088 (67.4) 3918 (70.1)‡ 3749 (68.8) 1257 (71.8)‡
Dyslipidemia, n (%) 1188 (73.6) 4014 (71.8) 3937 (72.2) 1265 (72.3)
Use of statins, n (%) 666 (41.2) 2231 (39.9) 2173 (39.9) 724 (41.4)
Type 2 diabetes, n (%) 776 (48.0) 2740 (49.0) 2640 (48.4) 876 (50.1)
Use of oral hypoglycemic agents, n (%) 440 (27.2) 1706 (30.5)‡ 1591 (29.2) 555 (31.7)‡
Use of insulin, n (%) 79 (4.9) 295 (5.3) 265 (4.9) 109 (6.2)‡
Values are n (%), except for age, weight, body mass index, and physical activity, expressed as means (95% CI). ALA indicates a-linolenic acid; CHD, coronary heart disease; ISSFAL,
International Society for the Study of Fatty Acids and Lipids; LCn-3PUFA, long-chain n-3 (x-3) polyunsaturated fatty acids; MET-min, minutes at a given metabolic equivalent level (units of
energy expenditure in physical activity, 1 MET-min is roughly equivalent to 1 kcal).
*0.7% energy, as a healthy ALA intake.
†A minimum intake of 500 mg/day of combined eicosapentaenoic and docosahexaenoic acids, for primary cardiovascular protection.
‡P<0.005 compared with participants meeting the recommendation (obtained by the chi-square test or ANOVA, as appropriate).
§P<0.005 compared with participants meeting the ALA recommendation (obtained by the chi-square test or ANOVA, as appropriate).
||Data from n=6997 participants (2979 men and 4018 women).
¶Data from n=6983 participants (2968 men and 4015 women).
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Dietary changes play a key role in protection against CVD,1
the leading cause of death worldwide.17 In this regard, the
intake of >250 mg/day of LCn-3PUFA (fulﬁlled by 95% of our
population) has been associated with a signiﬁcant reduction
of fatal CHD in healthy populations.18 The association is less
clear for randomized controlled trials of supplemental LCn-
3PUFA for secondary CVD prevention,19 although the
methodological issues in these trials (in particular, statistical
power, the length of intervention, background diet, and drug
use) might preclude drawing ﬁrm conclusions, as recently
noted.20 Based on large prospective population studies and
case-control studies mainly conducted in the United States,
ISSFAL recommended in 2004 an intake of at least 500 mg/
day of LCn-3PUFA. This goal can be achieved by following the
recommendation of the American Heart Association to
consume 2 weekly servings of ﬁsh, preferably oily ﬁsh.3 In
our population, meeting the ISSFAL recommendation for LCn-
3PUFA reduced the risk of fatal CVD; however, observational
studies suggest that LCn-3PUFA protects against fatal CHD,
particularly SCD, rather than fatal CVD.21 This effect,
observed with even a modest dietary intake of LCn-3PUFA,
is believed to be due to cardiac membrane accretion of EPA
and DHA, with ensuing improvement of myocardial oxygen
consumption efﬁciency, which contributes to limit myocardial
damage on ischemia.22 In our cohort, LCn-3PUFA intake
related to lower CHD mortality and, in examining the
association with SCD, despite the low number of events
(n=32), we found a trend (P=0.069) for protection, with a 52%
Table 3. Baseline Intake of Energy, Nutrients, and Key Foods by Sex
All Participants (n=7202) Men (n=3063) Women (n=4139)
Energy intake, kcal/day 2235 (2223–2248) 2408 (2388–2427) 2108 (2093–2123)
Carbohydrate, g/day 234 (233–236) 248 (245–251) 224 (222–226)
Fiber, g/day 25.2 (25.0–25.4) 25.7 (25.4–26.0) 24.9 (24.6–25.2)
Protein, g/day 91 (91–92) 94 (94–95) 89 (88–90)
Fat* 97 (96–98) 103 (102–104) 92 (92–93)
Saturated fatty acids 24.8 (24.6–25.0) 26.5 (26.2–26.9) 23.5 (23.3–23.8)
Monounsaturated fatty acids 48.2 (47.8–48.5) 51.3 (50.8–51.9) 45.9 (45.4–46.3)
n-6 polyunsaturated fatty acids 13.0 (12.8–13.1) 13.9 (13.7–14.1) 12.2 (12.1–12.4)
ALA 1.40 (1.38–1.42) 1.49 (1.46–1.53) 1.34 (1.31–1.36)
ALA, % of energy 0.06 (0.06–0.06) 0.06 (0.06–0.06) 0.06 (0.06–0.06)
Meeting the ISSFAL recommendation for a healthy ALA intake, n (%)† 1615 (22.4) 682 (22.3) 933 (22.5)
LCn-3PUFA 0.84 (0.83–0.85) 0.88 (0.86–0.90) 0.80 (0.79–0.82)
Meeting the ISSFAL recommendation for LCn-3PUFA, n (%)‡ 5452 (75.7) 2431 (79.4) 3021 (73.0)
Cholesterol, mg/day 361 (359–364) 382 (377–386) 346 (343–343)
Cereals, g/day 143 (141–145) 161 (158–164) 129 (127–132)
Vegetables, g/day 334 (331–337) 333 (327–338) 335 (331–340)
Fruits, g/day 368 (364–373) 365 (358–372) 371 (365–377)
Total nuts, g/day 10.1 (9.8–10.4) 11.2 (10.7–11.7) 9.3 (8.9–9.7)
Walnuts, g/day 5.9 (5.7–6.1) 6.2 (5.9–6.6) 5.7 (5.4–5.9)
Dairy products, g/day 380 (375–385) 342 (335–350) 408 (401–415)
Red meat, g/day 76 (75–77) 88 (86–90) 68 (67–69)
Seafood, g/day§ 99 (98–100) 102 (100–104) 97 (95–98)
Alcohol, g/day 9.1 (8.8–9.4) 15.4 (14.7–16.0) 3.1 (2.9–3.3)
Adherence to Mediterranean Diet|| 8.67 (8.62–8.71) 8.78 (8.71–8.84) 8.59 (8.53–8.71)
Values are n (%) or means (95% CI). ALA indicates a-linolenic acid; ISSFAL, International Society for the Study of Fatty Acids and Lipids; LCn-3PUFA, long-chain n-3 (x-3) polyunsaturated
fatty acids.
*Otherwise stated, values in g/day.
†0.7% of total energy intake.
‡A minimum intake of 500 mg/day of combined eicosapentaenoic acid and docosahexaenoic acid, for primary cardiovascular protection.
§Sum of uncanned fatty ﬁsh; lean ﬁsh; smoked/salted ﬁsh; molluscs; shrimp, prawn, and crayﬁsh; octopus, baby squid, and squid; fatty ﬁsh canned in oil; and fatty ﬁsh canned in salted
water.
||Determined by 12 questions on food consumption frequency and 2 questions on food intake habits characteristic of the Mediterranean diet (each question scored 0 or 1).
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reduced risk. Consequently, our results regarding SCD concur
in direction, if not in magnitude, with results from prior larger
studies. Importantly, our ﬁndings also support the hypothesis
that the customarily high intake of ﬁsh as part of the MedDiet
in Spain might contribute to explain the paradox of low rates
of both incident CHD and cardiac death,17,23,24 despite a high
burden of cardiovascular risk factors.25
Evidence regarding the cardiovascular beneﬁts of marine n-
3 notwithstanding, both low customary ﬁsh consumption in
most Western societies9 and the unsustainability of ﬁshing
prompted the search for alternative dietary sources of n-3
fatty acids. ALA is an n-3 that is available from plant sources
(mainly ﬂaxseeds, walnuts, soy products, and vegetable oils
such as canola and olive oil) and that is inexpensive.26
Although the evidence from large prospective studies and
randomized controlled trials is strong on the cardioprotective
effects of EPA and DHA, data on ALA are limited.27 Two
clinical studies have examined the effects of ALA on hard CVD
end points, the Lyon Diet Heart study28 and the Alpha-Omega
trial,29 both conducted in myocardial infarction survivors. A
Table 4. Baseline Intake of Energy, Nutrients, and Key Foods by Meeting the ISSFAL Recommendations
Meeting the ISSFAL Recommendation for ALA* Meeting the ISSFAL Recommendation for LCn-3PUFA†
Yes (n=1615) No (n=5587) Yes (n=5452) No (n=1750)
Energy intake, kcal/day 2320 (2294–2347) 2210 (2196–2225)‡ 2300 (2286–2314) 2033 (2008–2058)‡
Carbohydrate, g/day 220 (218–222) 239 (237–240)‡ 230 (229–231)§ 249 (247–251)‡
Fiber, g/day 26.8 (26.5–27.2) 24.8 (24.6–25.0)‡ 25.2 (25.0–25.4)§ 25.4 (25.0–25.7)
Protein, g/day 93 (92–93) 91 (90–91)‡ 93 (93–94) 85 (84–85)‡
Fat|| 104 (103–104) 95 (95–96)‡ 98 (98–99)§ 94 (93–95)‡
Saturated fatty acids 25.1 (24.9–25.4) 24.7 (24.6–24.9)‡ 25.0 (24.8–25.2) 24.2 (23.9–24.5)‡
Monounsaturated fatty acids 49.0 (48.4–49.5) 48.0 (47.7–48.3)‡ 48.8 (48.5–49.1) 46.3 (45.8–46.8)‡
n-6 polyunsaturated fatty acids 17.1 (16.9–17.3) 11.8 (11.7–11.9)‡ 12.9 (12.8–13.0)§ 13.2 (12.9–13.4)
ALA 2.63 (2.61–2.65) 1.05 (1.04–1.06)‡ 1.43 (1.41–1.45)§ 1.32 (1.28–1.36)‡
ALA, % of energy 0.12 (0.12–0.12) 0.05 (0.05–0.05)‡ 0.059 (0.057–0.060)§ 0.064 (0.063–0.065)‡
Meeting the ISSFAL recommendation
for a healthy ALA intake, n (%)
— — 4156 (76.2) 1296 (23.8)‡
LCn-3PUFA 0.89 (0.87–0.92) 0.82 (0.81–0.83)‡ 0.99 (0.98–1.00)§ 0.37 (0.35–0.39)‡
Meeting the ISSFAL recommendation
for LCn-3PUFA, n (%)
1296 (80.2) 319 (19.8)‡ — —
Cholesterol, mg/day 357 (352–362) 363 (360–366)‡ 376 (373–379)§ 316 (311–321)‡
Cereals, g/day 132 (128–135) 146 (144–148)‡ 145 (143–147)§ 137 (133–141)‡
Vegetables, g/day 353 (346–360) 329 (325–332)‡ 346 (342–350) 297 (291–304)‡
Fruits, g/day 399 (389–409) 359 (354–365)‡ 373 (367–378)§ 355 (345–365)‡
Total nuts, g/day 27 (27–28) 5 (5–5)‡ 11 (10–11)§ 8 (8–9)‡
Walnuts, g/day 19.4 (18.9–19.9) 2.0 (2.0–2.1)‡ 6.3 (6.0–6.5)§ 4.8 (4.4–5.2)‡
Dairy products, g/day 372 (361–382) 383 (377–388) 376 (371–382) 391 (381–402)‡
Red meat, g/day 80 (77–82) 75 (74–77)‡ 81 (80–82) 61 (60–63)‡
Seafood, g/day¶ 105 (103–108) 97 (96–98)‡ 113 (112–114)§ 55 (54–57)‡
Alcohol, g/day 7.4 (6.8–8.1) 8.6 (8.2–8.9)‡ 7.7 (7.1–8.4)§ 8.5 (8.2–8.9)‡
Adherence to Mediterranean Diet# 9.43 (9.34–9.51) 8.45 (8.40–8.50)‡ 8.88 (8.83–8.93)§ 8.02 (7.93–8.10)‡
Values are n (%) or means (95% CI). ALA indicates a-linolenic acid; ISSFAL, International Society for the Study of Fatty Acids and Lipids; LCn-3PUFA, long-chain n-3 (x-3) polyunsaturated
fatty acids.
*0.7% of total energy intake.
†A minimum intake of 500 mg/day of combined eicosapentaenoic acid and docosahexaenoic acid, for primary cardiovascular protection.
‡P<0.005 compared with participants meeting the recommendation (obtained by the chi-square test or ANOVA, as appropriate).
§P<0.005 compared with participants meeting the ALA recommendation (obtained by the chi-square test or ANOVA, as appropriate).
||Otherwise stated, values in g/day.
¶Sum of uncanned fatty ﬁsh; lean ﬁsh; smoked/salted ﬁsh; molluscs; shrimp, prawn, and crayﬁsh; octopus, baby squid, and squid; fatty ﬁsh canned in oil; and fatty ﬁsh canned in salted
water.
#Determined by 12 questions on food consumption frequency and 2 questions on food intake habits characteristic of the Mediterranean diet (each question scored 0 or 1).
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large beneﬁt in reduction of reinfarction in the Lyon study
could not be ascribed entirely to ALA, as other dietary
changes took place,28 whereas the Alpha-Omega trial
revealed a trend toward CVD protection for ALA in patients
receiving up-to-date cardiologic treatment.29 There have been
no primary prevention trials with ALA, only observational
studies. Many of these studies have been carried out in US
populations30–32 that are characterized by low ﬁsh consump-
tion,9 and data from the Health Professionals Follow-up Study
suggest that ALA protects against CHD only in this situa-
tion.30 In line with this, studies in mice reported that diets rich
in ALA are protective against endothelial dysfunction and
plaque inﬂammation,33 although this effect appears to be
modest compared with DHA.34 This might explain why, in our
population with high ﬁsh consumption, we could not detect a
cardioprotective effect of ALA; it was probably overrun by the
concomitant high intake of EPA and DHA with a stronger
beneﬁt against CHD. Alternatively, an eventual protective
effect of ALA against fatal cardiovascular outcomes could
have been masked by participants who met the ALA
recommendation being the healthiest subsample among the
study population (Table 2).
In contrast, we found that PREDIMED participants meeting
the ISSFAL recommendation for dietary ALA intake at baseline
had signiﬁcantly decreased risk of all-cause mortality by 28%.
These results concur with those of Koh and collaborators35 in
a large sample of Chinese adults in whom ALA intake was
inversely associated with all-cause mortality in the setting of
moderately high intakes of EPA plus DHA, albeit lower than in
our cohort. The highest reduction in all-cause mortality was
observed in participants meeting both ALA and LCn-3PUFA
recommendations (Table 6), suggesting that the 2 n-3 fatty
acids (or their parent foods) are partners in reducing the risk
of total mortality. Given that the almost exclusive source of
ALA in our population was consumption of walnuts, followed
by olive oil, this association may be attributable not only to
ALA per se but also to other components of the parent foods,
such as polyphenols, tocopherols, and phytosterols, all with
salutary properties.36 This notion is consistent with prior
evidence on reduced all-cause mortality associated with the
consumption of nuts37–39 and walnuts, in particular,39 and
olive oil.40 Consequently, it is plausible that in a Mediter-
ranean population, reduced all-cause mortality associated
with ALA intake relates to the bioactive components of
walnuts and olive oil (including ALA itself), with dietary ALA
being a surrogate marker of the consumption of the parent
foods. Such a hypothesis is reinforced by the fact that, when
Table 5. Risk of All-Cause and Cardiovascular Mortality for Meeting the ISSFAL Recommendation of a Healthy Intake of ALA (0.7%
of Energy) and LCn-3PUFA Consumption for Primary Cardiovascular Prevention (at Least 500 mg/day)
End point (No. of Events)
ALA LCn-3PUFA
HR (95% CI) P Value HR (95% CI) P Value
Total mortality (431) 0.722 (0.558–0.933) 0.013 0.837 (0.667–1.050) 0.124
Fatal CVD (104) 0.953 (0.579–1.566) 0.848 0.614 (0.393–0.960) 0.032
Fatal CHD (55) 0.752 (0.359–1.578) 0.451 0.537 (0.292–0.988) 0.046
Sudden cardiac death (32) 0.768 (0.288–2.049) 0.598 0.485 (0.223–1.057) 0.069
Fatal stroke (25) 1.288 (0.492–3.373) 0.607 0.779 (0.298–2.036) 0.610
Data are given as HRs and 95% CIs, using as reference category the groups not meeting recommended daily ALA or LCn-3PUFA intake. Multivariable Cox regression model, stratiﬁed for
recruiting node; adjusted for age, sex, intervention group, body mass index, smoking status (never, former, or current smoker), physical activity (minutes at a given metabolic equivalent
level per day), total energy intake (kcal/day), history of diabetes (yes or no), history of hyperlipidemia (yes or no), history of hypertension (yes or no), alcohol intake (g/day), and dietary
factors (ﬁber, vegetables, fruits, and red meat), reciprocally adjusted for meeting recommended ALA or LCn-3PUFA intake. ALA indicates a-linolenic acid; CHD, coronary heart disease; CVD,
cardiovascular disease; HR, hazard ratio; ISSFAL, International Society for the Study of Fatty Acids and Lipids; LCn-3PUFA, long-chain n-3 (x-3) polyunsaturated fatty acids.
Table 6. Risk of All-Cause Mortality for Meeting None, One,
or Both ISSFAL Recommendations of n-3 Fatty Acid Intake
HR (95% CI) P Value
Meeting neither recommended ALA
nor LCn-3PUFA intake (n=1431)
1.00 —
Only meeting the recommendation
of LCn-3 PUFA intake for primary
cardiovascular prevention (at least
500 mg/day) (n=4156)
0.781 (0.615–0.994) 0.044
Only meeting the recommendation
of a healthy intake of ALA (0.7% of
energy) (n=319)
0.670 (0.551–0.977) 0.018
Meeting both recommendations
(n=1296)
0.626 (0.450–0.871) 0.005
Data are given as HRs and 95% CIs, using as reference category the group meeting
neither recommended ALA nor LCn-3PUFA intake. A multivariable Cox regression model
was stratiﬁed for recruiting node and adjusted for age, sex, intervention group, body
mass index, smoking status (never, former, or current smoker), physical activity (minutes
at a given metabolic equivalent level per day), total energy intake (kcal/day), history of
diabetes (yes or no), history of hyperlipidemia (yes or no), history of hypertension (yes or
no), alcohol intake (g/day), and dietary factors (ﬁber, vegetables, fruits, and red meat).
ALA indicates a-linolenic acid; CHD, coronary heart disease; CVD, cardiovascular
disease; HR, hazard ratio; ISSFAL, International Society for the Study of Fatty Acids and
Lipids; LCn-3PUFA, long-chain n-3 (x-3) polyunsaturated fatty acids.
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considering the 3 intervention groups in the trial, the highest
reduction in mortality was observed in the participants
allocated to the MedDiet supplemented with extra virgin olive
oil, suggesting that phytochemicals with antioxidant and anti-
inﬂammatory properties contained in extra virgin olive oil
might act synergistically with walnut-derived bioactive com-
pounds.
Our study has several limitations. First, we had a relatively
low number of fatal cardiovascular events, resulting in
imprecise estimates. Second, nutrient exposures were esti-
mated with a food-frequency questionnaire, which has the
potential of misclassiﬁcation bias. An objective biomarker
(circulating or adipose tissue fatty acids) would have provided
more accurate estimation of ALA intake. Third, residual
confounding is possible in a longitudinal cohort analysis, but
we adjusted for many possible confounders, including recip-
rocal adjustment for the 2 types of n-3 fatty acids examined.
Fourth, given the advice to increase adherence to a MedDiet
(in 2 PREDIMED arms) and the nut supplementation (in 1
arm), cumulative average estimates of exposures of interest
would provide a more robust measure than a single baseline
assessment. Finally, the generalizability of our results is
limited, given that participants were older persons at high
cardiovascular risk living in a Mediterranean country. There
are also strengths to our study, such as a large sample size,
relative homogeneity of participants, a prospective design,
thorough ascertainment of mortality, validation of the food-
frequency questionnaire, and adjustment for relevant con-
founders.
In conclusion, our results add supporting evidence to the
notion that, in a population at high cardiovascular risk but no
prior CVD with a customarily high consumption of seafood,
dietary ALA relates inversely to all-cause mortality, but
protection from cardiovascular and cardiac death is limited
to ﬁsh-derived EPA plus DHA. ALA intake was derived mostly
from walnuts and olive oil, both sources of phytochemicals
with antioxidant and anti-inﬂammatory properties besides
ALA. The highest reductions in mortality were observed in
participants meeting the ISSFAL recommendation for ALA
intake allocated to the MedDiet plus extra virgin olive oil arm
and in participants meeting the recommendations for both
LCn-3PUFA and ALA intake. This suggests that, together with
Figure. Adjusted hazard ratios of total mortality by meeting the ISSFAL recommendation for a healthy ALA
intake and PREvencion con DIeta MEDiterranea (PREDIMED) intervention group. Data are given as hazard
ratios. A multivariable Cox regression model was stratiﬁed for recruiting node and adjusted for age, sex,
body mass index, current smoking status (never, former, or current smoker), physical activity (minutes at a
given metabolic equivalent per day), total energy intake (kcal/day), history of diabetes (yes or no), history of
hyperlipidemia (yes or no), history of hypertension (yes or no), alcohol intake (g/day), dietary factors (ﬁber,
vegetables, fruits, and red meat), and meeting the ISSFAL recommendation of eicosapentaenoic acid and
docosahexaenoic acid consumption for primary cardiovascular prevention (yes or no). Values for the “not
meeting the recommendation” category are 1.00 (reference) for the low-fat control diet group, 0.94 (95% CI,
0.73–1.23) for the MedDiet supplemented with nuts (MedDiet plus nuts) group, and 0.97 (95% CI 0.76–
1.24) for the MedDiet supplemented with extra virgin olive oil (MedDiet plus EVOO). Values for the “meeting
the recommendation” category are 0.81 (95% CI 0.52–1.25) for the control diet group, 0.71 (95% CI 0.47–
1.06) for the MedDiet plus nuts group, and 0.59 (95% CI 0.36–0.96) for the MedDiet plus EVOO group.
EVOO indicates extra virgin olive oil; ISSFAL, International Society for the Study of Fatty Acids and Lipids;
MedDiet, Mediterranean diet.
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the MedDiet pattern, marine and vegetable n-3 fatty acids (or
their parent foods) act synergistically and are partners rather
than competitors in reducing mortality.
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